MedPath

Clinical assessment of serum hepcidin isoforms associated with iron homeostasis and erythropoiesis-stimulating agent response in CKD patients

Not Applicable
Conditions
CKD
Registration Number
JPRN-UMIN000003427
Lead Sponsor
iizuka Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
400
Inclusion Criteria

Not provided

Exclusion Criteria

These patients were excluded with severe inflammatory disease, infection, cancer, hematological disorders or blood transfusion within 4 weeks.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The relationship between the change of serum hepcidin and the responsiveness to erythropoiesis-stimulating agent
Secondary Outcome Measures
NameTimeMethod
To evaluate the association of serum hepcidin, iron-related biomarker, erythropoitic activity and serum cytokine
© Copyright 2025. All Rights Reserved by MedPath